Certara, Inc. (CERT) Dividend History

Company News

• 3 Momentum Stocks That Could Soar Post-Market Volatility

  Three companies in the software-based drug development and furniture industries have emerged as momentum plays following a period of market volatility. Certara, Schrodinger, and Lovesac have seen their stock prices rise significantly due to positive news, technological advancements, and adaptable business models.

  Investing.com

  Featured Companies: LOVE SDGR
• These Mid-Cap Stocks Outshone The Market Volatility Last Week (Apr 7-Apr 11): Are These In Your Portfolio?

  Several mid-cap stocks outperformed the market during the volatile week of April 7-11, including AeroVironment, Recursion Pharmaceuticals, Certara, and Agilon Health. The gains were driven by factors such as FDA reforms, tariff pauses, and positive news for the companies.

  Benzinga

  Featured Companies: AGL AVAV RXRX
• What's Going On With Charles River, Certara, Simulations Plus Stocks On Friday?

  The FDA announced a major shift towards adopting human-relevant and technologically advanced testing methods, including AI-based simulations and lab-grown organoids, to evaluate monoclonal antibody therapies and other drugs, reducing the reliance on traditional animal testing.

  Benzinga

  Featured Companies: CRL SLP
• Biosimulation Industry Forecast, 2029: Analysis of Case Studies, Market Dynamics, Regional Growth Trends, Regulatory Landscape, Value Chain, and Competitive Intelligence

  The biosimulation market is projected to reach USD 9.18 billion by 2029, growing at a CAGR of 16.7% from 2024 to 2029. The market is driven by the increasing need for cost and time reduction in the drug development process, but high costs of biosimulation technologies remain a restraint.

  GlobeNewswire Inc.

  Featured Companies: ANSS SDGR SLP
• Certara Completes Acquisition of Chemaxon

  Certara, a global leader in model-informed drug development, has completed the acquisition of Chemaxon, a leading cheminformatics company. The combined expertise of the two companies is expected to enhance productivity and increase scientific innovation success rates in the life sciences industry.

  Benzinga